Using Cannabis America to remove abuse potential of opioids

Bazelet’s solutions targeting ways to fix opioid epidemic using chemicals found in cannabis sativa but providing material for research free of THC while retaining all entourage effective Endocannabinoid system impact from cannabis America plants grown 0.000% THC and in research legally used in trials shows ability and promise still alleviating pain and avoid side effects that come with that. Opportunities and potential separating out the respiratory failure , the overdose from pain relieving properties. The ability to get some effects while not enduring other effects is the true science and with human trials using cannabis America Bazelet health see the potential to remove abuse potential of opioid addiction.

Can Medicinal Cannabis Substitute for Opioids? Bazelet health comparing the effectiveness of opiate vs. cannabis-based products on chronic pain. The absence of these studies are related to the federal barriers to conducting research using marijuana and the difficulty of getting them ethically approved. A true random clinical trial would involve randomizing chronic pain patients to take either a FDA approved product or a Schedule 1 drug (the federal classification meaning that a substance has no medical benefits and high abuse potential). Fortunately, policies permitting research are slowly changing at a state level: Colorado Public Health Department has funded a RCT using state marijuana taxes on this very topic. The study, which will be completed in 2020, will assess for the first time how cannabis compares to Oxydone and placebo in reducing chronic back and neck pain.

Meanwhile, many people suffering from chronic pain have access to cannabis in the US: relief from pain is by far the most frequent condition reported by medical cannabis patients while potentially in using compounds found in cannabis America used in low dose with fda approved pain relief medication is where we can improve current medication not just turning on or off but fine running to still use pain relieving approved medications with less risk of side effects
The use of cannabis to complement or substitute for opiates in the treatment of chronic pain has been described in numerous studies, despite the absence of randomized trials comparing opiate based and cannabis-based medications in terms of effectiveness, functionality and quality of life.

The need for more funding and fewer barriers to conduct studies on the benefits and risks of cannabis can be immediately solved with 0.000 % hemp. Evidence so far suggests that cannabis may have an important role both in addressing the chronic pain epidemic and the opioid crisis in the U.S. Knowing more is a matter of public health safety.

Cannabis use is not without risk and the boundaries between its use for medicinal and mind-altering purposes are a sham. Research available to date has not been conducted with the products current consumers actually use could lead to more federal prosecution of the plant as medical products are recreational in current marketplace and with profits and nee equipment cartels leading corporate adult use cannabis have products if allowed full scientist to access these products could potentially make US policy remain restrictive and concerning for law enforcement.

Still medicine and cannabis means green which biosciences and GW pharmaceutical globally and continued steps as seen by The National Institutes of Health (NIH) recently awarded grant to researchers at Albert Einstein College of Medicine and Montefiore Health System for a prospective cohort study that will follow up 250 patients with recent MC certification, severe chronic pain, and opioid use for 18 months. The study started in 2018 and is expected to be completed in 2022; its overall goal was to understand how medical cannabis use affects opioid analgesic use over time, with particular attention to THC/CBD content, HIV outcomes, and adverse events. (

Some state funded research sponsored by cannabis taxes is expected to continue, as public opinion exerts pressure for science based answers to cannabis legalization but currently we believe the landscape regarding research on medicinal cannabis must change, Bazelet health leading policy and practice that is informed by improved research evidence not using research and published reports to drive sales of recreational weed.

GW hired a vociferous medical marijuana opponent to help them distinguish their version of THC from medical cannabis. Still to this day the FDA has not approved Sativex because this brings THC as medicine just as Epidiolex once FDA made cannabidiol CBD medicine.

And where did it get its cannabis genetics? What is the difference from any other plants or seeds? GW Pharmaceuticals entered into a contract with two expert horticulturists, and grew and developed strains of cannabis with permission from the Dutch government as these individuals develop plants that simultaneously created the current coffee shop Amsterdam marijuana seen known globally and genetics that provide today’s entire genetic library for cannabis sativa L. 0.000% plants and a nee focus on hemp and the use of plant tissue culture labs and heirloom landrace genetics to build a opportunity for the clear path of cannabis forward is Cannabis America.